Statins and hemoperfusion improve 28-day survival in septic shock patients

Tsukasa Nakamura, Eiichi Sato, Nobuharu Fujiwara, Yasuhiro Kawagoe, Sayaka Maeda, Hiroyoshi Inoue, Sho Ichi Yamagishi

研究成果: Article査読


Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R 2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.

ジャーナルCentral European Journal of Medicine
出版ステータスPublished - 2012 8月

ASJC Scopus subject areas

  • 医学(全般)


「Statins and hemoperfusion improve 28-day survival in septic shock patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。